ArticleCancers2022
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Early thyroid-stimulating hormone dynamics predict outcomes in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab.Surgery today · 2026Article
- Review
- Prognostic significance of Albumin-Bilirubin score changes in patients treated with systemic therapy for recurrent hepatocellular carcinoma after liver resection.Surgery today · 2026Article
- Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC.JHEP reports : innovation in hepatology · 2026Article
- Emergence of Liquid Biopsy in Precision Oncology: A Review of its diagnostic, Predictive and Therapeutic Applications in Gallbladder Cancer.Journal of gastrointestinal cancer · 2026Review
- Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).Therapeutic advances in medical oncology · 2026Article
- Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity.JHEP reports : innovation in hepatology · 2025Article
- Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study.Therapeutic advances in medical oncology · 2025Article
- Article
- Immunologic tumor microenvironment modulators for turning cold tumors hot.Cancer communications (London, England) · 2024Review
- Analysis of Somatic Mutations in the TCGA-LIHC Whole Exome Sequence to Identify the Neoantigen for Immunotherapy in Hepatocellular Carcinoma.Current issues in molecular biology · 2023Article
- Review
- A case of granulocyte-colony-stimulating factor-producing gallbladder cancer with lymph node metastasis together with a literature review.Clinical journal of gastroenterology · 2023Review
- Article
- Liver Cancer: Improving Standard Diagnosis and Therapy.Cancers · 2023Article
- Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.EClinicalMedicine · 2023Article
- Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 15 institutions in 2 countries.
Friedrich SinnerDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital Magdeburg, 39120 Magdeburg, Germany.ORCID 0000-0003-0524-8833
Matthias PinterDepartment of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, A-1090 Vienna, Austria.ORCID 0000-0002-7260-532X
Bernhard ScheinerDepartment of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, A-1090 Vienna, Austria.ORCID 0000-0002-4904-5133
Thomas Jens EttrichUlm University Hospital, Department of Internal Medicine I, 89081 Ulm, Germany.ORCID 0000-0002-7654-2442
Niklas SturmUlm University Hospital, Department of Internal Medicine I, 89081 Ulm, Germany.ORCID 0000-0001-9219-0099
Maria A Gonzalez-CarmonaDepartment of Internal Medicine I, University Hospital of Bonn, 53127 Bonn, Germany.ORCID 0000-0003-3956-1457
Oliver WaidmannDepartment of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Fabian FinkelmeierDepartment of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, 60590 Frankfurt, Germany.ORCID 0000-0001-8559-9910
Vera HimmelsbachDepartment of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, 60590 Frankfurt, Germany.
Enrico N De ToniDepartment of Medicine II, University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0002-8101-8207
Najib Ben KhaledDepartment of Medicine II, University Hospital, LMU Munich, 81377 Munich, Germany.ORCID 0000-0002-9681-2542
Raphael MohrDepartment of Hepatology & Gastroenterology, Campus Virchow Klinikum and Campus Charité Mitte, Charité University Medicine Berlin, 10117 Berlin, Germany.ORCID 0000-0003-2403-4275
Thorben Wilhelm FründtDepartment of Internal Medicine, Gastroenterology & Hepatology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Fabian KüttingClinic for Gastroenterology and Hepatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
Florian van BömmelDepartment of Medicine II, Division of Hepatology, Leipzig University Medical Center, 04103 Leipzig, Germany.ORCID 0000-0003-2679-0672
Sabine LiebDepartment of Medicine II, Division of Hepatology, Leipzig University Medical Center, 04103 Leipzig, Germany.
Sebastian KrugDepartment of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany.ORCID 0000-0003-1672-7995
Dominik BettingerDepartment of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.ORCID 0000-0002-8782-8729
Michael SchultheißDepartment of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Leonie S JochheimDepartment of Gastroenterology and Hepatology, University Hospital Essen, 45147 Essen, Germany.
Jan BestDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital Magdeburg, 39120 Magdeburg, Germany.
Christian MüllerDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital Magdeburg, 39120 Magdeburg, Germany.ORCID 0000-0002-6881-1817
Verena KeitelDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital Magdeburg, 39120 Magdeburg, Germany.
Marino VeneritoDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital Magdeburg, 39120 Magdeburg, Germany.ORCID 0000-0001-8581-0974
University Hospital Magdeburg · DEGoethe University Frankfurt · DELeipzig University · DEMedical University of Vienna · ATUniversity Hospital Ulm · DEUniversity of Freiburg · DECharité - Universitätsmedizin Berlin · DEEssen University Hospital · DEGerman Cancer Research Center · DELMU Klinikum · DEMartin Luther University Halle-Wittenberg · DEUniversität Hamburg · DEUniversitätsklinikum Knappschaftskrankenhaus Bochum · DEUniversity Hospital Bonn · DEUniversity of Cologne · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atezolizumab plus bevacizumab is the standard of care for first-line systemic therapy for advanced hepatocellular carcinoma (aHCC). Data on the efficacy and safety of atezolizumab plus bevacizumab in patients with aHCC who have received prior systemic therapy are not available.
Indexed as
atezolizumabbevacizumabhepatocellular carcinomaimmune checkpoint inhibitionimmunotherapyliver cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.